# Liposomal Irinotecan and Apatinib in ES-SCLC

> **NCT06749691** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Liposomal Irinotecan and Apatinib

## Key facts

- **NCT ID:** NCT06749691
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-28
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749691, "Liposomal Irinotecan and Apatinib in ES-SCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06749691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*